Mexico’s Patent Office, COFEPRIS Sign Agreement on Drug Patents

Officials with Mexico’s patent office and its pharmaceutical regulator have signed a new agreement aimed at preemptively clarifying patent protections for drugs in hopes of speeding the review process.
The end of paper at Anvisa! Electronic Protocol is the future of Health Surveillance

The Brazilian Health Surveillance Agency (ANVISA) will fully adopt the electronic document protocol from March 13, 2025, as established by RDC 947/2024. This change will eliminate the need for paper documents, promoting greater agility in document analysis, modernizing processes and reducing operating costs, especially those related to digitization and physical storage.
RDC 954/2024 -Comprehending the Highlights and Impacts on Drug Registration

The National Health Surveillance Agency (ANVISA) has launched Collegiate Board Resolution, RDC 954/2024 introduces several updates to make the drug registration process more agile and in line with international standards. .
ANVISA Publishes Database for Clinical Investigations into Medical Devices

The National Health Surveillance Agency (ANVISA) has announced the launch of a database aimed at clinical investigations related to medical devices. This initiative represents an important milestone in the health sector, promoting greater transparency, efficiency and safety in research carried out in Brazil.
Transfer certificate of GMP and Ownership of Products: What Companies Need to Know

The transfer of Good Manufacturing Practice Certificates (GMP) at Anvisa is a specific process, usually related to changes in certificate ownership due to corporate reorganization, such as mergers or acquisitions.
ANVISA Intensifies Monitoring of Generic Drugs: New Requirements in Force

The National Health Surveillance Agency (Anvisa) recently announced a new package of regulatory measures aimed at strengthening the monitoring of generic drugs in Brazil. The aim is to ensure even greater safety and efficacy for these products, which are widely used by the population and represent a significant part of the national pharmaceutical market.
Clinical Trials for Drugs/Medicines in Brazil and the Clinical Trial Application process

In Brazil, clinical trials for drugs follow strict regulations, guaranteeing the safety of participants and the efficacy of the drugs being tested. The regulatory body responsible is the National Health Surveillance Agency (ANVISA), which establishes rules for conducting these studies.
Anvisa approves release of vaccine and medicine against monkey pox

Anvisa approves release of vaccine and medicine against monkey pox
Brazil’s Anvisa approves eighth cannabis-based medicinal product

Resolution RDC No.327/2019 establishes requirements for the marketing of cannabis products for medicinal purposes. So far, there are eight cannabis products approved by ANVISA.
Brazil’s Chamber for Drug Market Regulation discloses the annual price adjustment for drugs

On January 10th, 2022, Brazil’s Technical-Executive Committee of the Drugs Market Regulation Chamber (CMED) set at 0% (zero percent) the value of the productivity factor (Factor X) referring to the adjustment of drug prices for the year 2022.
Brazil’s Anvisa approves eighth cannabis-based medicinal product

Resolution RDC No.327/2019 establishes requirements for the marketing of cannabis products for medicinal purposes. So far, there are eight cannabis products approved by ANVISA.
Brazil’s Anvisa approves two new cannabis-based products

The Resolution RDC No.327/2019 establishes requirements for the marketing of cannabis products for medicinal purposes. So far, there are seven cannabis products approved by ANVISA.